Figure 2.

Mean plasma concentration in healthy volunteers vs. time profiles for Treatment A (OROS^® hydromorphone 16 mg; fasting conditions) and Treatment C (OROS^® hydromorphone 16 mg; fasting conditions and naltrexone block).